The Food and Drug Administration announced Wednesday that it would seek to pull a widely used ingredient in cough and cold medicines from the market, after the agency's scientists concluded that the oral version of the drug is ineffective as a nasal decongestant.
The industry trade group renewed its claim that no changes 'are warranted' for oral phenylephrine and cited previous FDA and advisory committee decisions that did not call for pulling the ingredient.'PE should remain an available option for consumers, because Americans deserve the option to choose the safe and effective OTC medicines they prefer and rely on,' Scott Melville, CHPA's president and CEO, said in a statement.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: